Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05347771 · ClinicalTrials.gov registry record · Phase 2
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
A Phase 2 study of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 8
- Study locations
NCT05347771 is a Phase 2 study of Asthma that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05347771, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (8)
New York
- Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute - New York
- Columbia University Medical Center: Division of Pediatric Pulmonology - New York
Colorado
- Children's Hospital Colorado: Allergy Program - Aurora
District of Columbia
- Children's National Medical Center: Children's Research Institute - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology - Chicago
Massachusetts
- Boston Children's Hospital: Department of Immunology - Boston
Missouri
- Washington University at St. Louis - St Louis
Ohio
- Cincinnati Children's Hospital Medical Center: Asthma Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05347771
The ClinicalTrials.gov registry entry for NCT05347771 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05347771 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05347771 about?
NCT05347771 is a clinical study titled "Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents". This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
What is the current status of trial NCT05347771?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2022-05-04. Estimated completion is 2027-03-15.
What conditions does trial NCT05347771 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05347771?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05347771?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05347771 being conducted?
This trial has 8 study locations across Colorado, District of Columbia, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.